High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation

Fox C. P., Boumendil A., Schmitz N., Finel H., Luan J. J., Sucak G., ...Daha Fazla

LEUKEMIA & LYMPHOMA, cilt.56, sa.12, ss.3295-3300, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 12
  • Basım Tarihi: 2015
  • Doi Numarası: 10.3109/10428194.2015.1037764
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3295-3300
  • Anahtar Kelimeler: Epstein-Barr virus, high-dose therapy, natural killer cell lymphoma, stem cell transplantation, NATURAL KILLER/T-CELL, PERIPHERAL T-CELL, NASAL-TYPE, L-ASPARAGINASE, CHEMOTHERAPY, STAGE, RADIOTHERAPY, MANAGEMENT, SMILE
  • Gazi Üniversitesi Adresli: Evet

Özet

Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.